PODD logo

PODD

Insulet Corporation

$145.76
+$2.24(+1.56%)
44
Overall
35
Value
40
Tech
57
Quality
How is this score calculated?
Market Cap
$20.84B
Volume
2.86M
52W Range
$140.63 - $354.88
Target Price
$237.57

Company Overview

Mkt Cap$20.84BPrice$145.76
Volume2.86MChange+1.56%
P/E Ratio84.3Open$144.64
Revenue$2.7BPrev Close$143.52
Net Income$247.1M52W Range$140.63 - $354.88
Div YieldN/ATarget$237.57
Overall44Value35
Quality57Technical40

No chart data available

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Sector: Healthcare
Industry: Medical Devices

Latest News

Overvalued? Analysts Say These 3 High P/E Stocks Could Jump 50%+

Using the TipRanks Stock Screener Tool, we identified three companies with high price-to-earnings (P/E) ratios, Strong Buy consensus ratings, and m...

Sheryl Sheth3 days ago

BTIG Remains a Buy on Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdesk3 days ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

Howard Kim9 days ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

Howard Kim9 days ago

Raymond James Sticks to Their Buy Rating for Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdesk12 days ago
ABCD
1SymbolPriceChangeVol
2PODD$145.76+1.6%2.86M
3
4
5
6

Get Insulet Corporation Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.